Recce Pharmaceuticals Ltd. (AU:RCE)

ASX:RCE

RCE

Recce Pharmaceuticals Ltd.

RESEARCH TOOLSreports

Want to see AU:RCE full AI Analyst Report?

Recce Pharmaceuticals Ltd. (RCE) Price & Analysis

21 Followers

RCE Stock Chart & Stats

AU$0.41

AU$0.00(0.00%)

At close: Jan 09 4:00 PM EST

AU$0.41

AU$0.00(0.00%)

Day’s Range― - ―

52-Week RangeAU$0.28 - AU$0.73

Previous CloseN/A

Volume21.12K

Average Volume (3M)154.69K

Market Cap

AU$150.38M

Enterprise ValueAU$172.84M

Total Cash (Recent Filing)AU$602.99K

Total Debt (Recent Filing)AU$11.26M

Price to Earnings (P/E)―

Beta0.70

Next Earnings

Aug 28, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.06

Shares Outstanding289,183,400

10 Day Avg. Volume112,630

30 Day Avg. Volume154,688

Financial Highlights & Ratios

PEG Ratio0.34

Price to Book (P/B)-22.52

Price to Sales (P/S)9.15

P/FCF Ratio-3.36

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.07

Revenue Forecast (FY)AU$4.25M

Bulls Say, Bears Say

Bulls Say

Platform-focused Anti-infective R&DRecce’s core business is a platform of synthetic polymer antibiotics targeting drug-resistant infections. A platform approach and clinical-stage pipeline create durable optionality: multiple candidates, shared R&D learnings, and potential partner licensing that support long-term value beyond any single trial outcome.

Free Cash Flow ImprovementA 51.97% rise in free cash flow indicates improving cash conversion trends despite losses. Sustained FCF improvement can extend clinical runways, reduce immediate financing pressure and support continued trials or partnering conversations, making funding needs less acute over a multi-month horizon.

Measured Capital Efficiency (positive ROE)A reported 7.02% ROE suggests management generates some return from the company’s equity base, reflecting operational focus and efficient use of invested capital. For a clinical-stage biotech, consistent capital efficiency can preserve investor confidence and help prioritize programs with higher expected returns.

Bears Say

Declining RevenueA 21.73% revenue decline reduces internal funding capacity and signals weaker commercial or partner-derived income. For a clinical-stage firm reliant on external financing, sustained top-line contraction erodes optionality, increases dependency on dilutive raises or partnerships, and pressures program continuity.

Severe Negative Profitability MarginsExtremely negative EBIT and net margins reflect high burn relative to revenues and indicate operations are not close to break-even. Persistent deep losses are structurally unsustainable without recurring funding and raise the likelihood of dilution or program delays, impairing long-term strategy execution.

Negative Equity And High LeverageNegative equity with a debt-to-equity of -3.53 shows liabilities exceed assets, limiting financial flexibility. This structural balance-sheet weakness elevates refinancing and solvency risk, likely forcing dilutive capital raises or restrictive lender terms that can constrain R&D investment choices over months.

Recce Pharmaceuticals Ltd. News

Recce Pharmaceuticals Options Lapse Trims Potential Share Dilution

Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) just unveiled an update. Recce Pharmaceuticals has notified the market of the...

4d ago

Recce Wins Brazilian Patent for Broad-Spectrum Anti-Infective Portfolio

Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) has shared an announcement. Recce Pharmaceuticals has secured a key Brazilian patent...

26d ago

Recce Pharmaceuticals Issues Webinar Disclaimer on Investor Information and U.S. Offer Restrictions

An announcement from Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) is now available. Recce Pharmaceuticals has released a webinar...

1M ago

Recce Pharmaceuticals Schedules Investor Webinar to Highlight Key Anti-Infective Programs

Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) has shared an announcement. Recce Pharmaceuticals will host a live online investor...

1M ago

Recce Pharmaceuticals Deepens R&D-Driven Loss as Anti-Infective Programs Advance

Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) just unveiled an announcement. Recce Pharmaceuticals reported a widened half-year loss of...

2M ago

Recce Pharmaceuticals Director Options Lapse Following Scheduled Expiry

Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) has provided an update. Recce Pharmaceuticals reported a change in the securities...

2M ago

Recce Pharmaceuticals Options Lapse, Simplifying Capital Structure

An announcement from Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) is now available. Recce Pharmaceuticals has announced the cessation...

2M ago

Recce Pharmaceuticals Deepens U.S. Army Ties With New Burn Wound Gel Study

Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) has provided an update. Recce Pharmaceuticals has signed a new Cooperative Research...

3M ago

Recce Advances Phase 3 Diabetic Foot Trial and Strengthens Anti-Infective Pipeline

An announcement from Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) is now available. Recce Pharmaceuticals reported significant operational progress...

3M ago

Recce Pharmaceuticals Secures $5.3m R&D Rebate to Bolster Anti-Infective Pipeline

Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) has issued an announcement. Recce Pharmaceuticals has received an AUD $5.34 million...

3M ago

RCE FAQ

What was Recce Pharmaceuticals Ltd.’s price range in the past 12 months?

Recce Pharmaceuticals Ltd. lowest share price was AU$0.28 and its highest was AU$0.73 in the past 12 months.

What is Recce Pharmaceuticals Ltd.’s market cap?

Recce Pharmaceuticals Ltd.’s market cap is AU$150.38M.

When is Recce Pharmaceuticals Ltd.’s upcoming earnings report date?

Recce Pharmaceuticals Ltd.’s upcoming earnings report date is Aug 28, 2026 which is in 131 days.

How were Recce Pharmaceuticals Ltd.’s earnings last quarter?

Recce Pharmaceuticals Ltd. released its earnings results on Feb 27, 2026. The company reported -AU$0.057 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.057.

Is Recce Pharmaceuticals Ltd. overvalued?

According to Wall Street analysts Recce Pharmaceuticals Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Recce Pharmaceuticals Ltd. pay dividends?

Recce Pharmaceuticals Ltd. does not currently pay dividends.

What is Recce Pharmaceuticals Ltd.’s EPS estimate?

Recce Pharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Recce Pharmaceuticals Ltd. have?

Recce Pharmaceuticals Ltd. has 289,183,400 shares outstanding.

What happened to Recce Pharmaceuticals Ltd.’s price movement after its last earnings report?

Recce Pharmaceuticals Ltd. reported an EPS of -AU$0.057 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.917%.

Which hedge fund is a major shareholder of Recce Pharmaceuticals Ltd.?

Currently, no hedge funds are holding shares in AU:RCE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Recce Pharmaceuticals Ltd. Stock Smart Score

Outperform

Fundamentals

Return on Equity

279.21%

Trailing 12-Months

Asset Growth

-51.48%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Recce Pharmaceuticals Ltd.

Recce Pharmaceuticals Ltd. (RCE) is a biotechnology company focused on the development and commercialization of innovative anti-infective therapies. The company specializes in creating synthetic polymers to combat serious infections, particularly those caused by antibiotic-resistant bacteria. Recce's lead product candidate, RECCE 327, is designed to treat a range of infections, including sepsis, and is positioned to address the growing global health challenge of antibiotic resistance.